192 related articles for article (PubMed ID: 9499094)
1. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
2. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants.
McCrackin Stevenson MA; McBroom DG
Am J Vet Res; 2001 Apr; 62(4):588-94. PubMed ID: 11327469
[TBL] [Abstract][Full Text] [Related]
4. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
Remington KM; Zhu YQ; Phillips TR; North TW
J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
[TBL] [Abstract][Full Text] [Related]
5. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
6. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
[TBL] [Abstract][Full Text] [Related]
7. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.
Remington KM; Chesebro B; Wehrly K; Pedersen NC; North TW
J Virol; 1991 Jan; 65(1):308-12. PubMed ID: 1845891
[TBL] [Abstract][Full Text] [Related]
8. Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.
Zhu YQ; Remington KM; North TW
Antimicrob Agents Chemother; 1996 Sep; 40(9):1983-7. PubMed ID: 8878567
[TBL] [Abstract][Full Text] [Related]
9. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
10. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
[TBL] [Abstract][Full Text] [Related]
11. A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
Smith RA; Klarmann GJ; Stray KM; von Schwedler UK; Schinazi RF; Preston BD; North TW
Antimicrob Agents Chemother; 1999 Aug; 43(8):2077-80. PubMed ID: 10428942
[TBL] [Abstract][Full Text] [Related]
12. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
[TBL] [Abstract][Full Text] [Related]
13. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
Götte M; Arion D; Parniak MA; Wainberg MA
J Virol; 2000 Apr; 74(8):3579-85. PubMed ID: 10729133
[TBL] [Abstract][Full Text] [Related]
14. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
15. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
[TBL] [Abstract][Full Text] [Related]
16. Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
Halvas EK; Svarovskaia ES; Freed EO; Pathak VK
J Virol; 2000 Jul; 74(14):6669-74. PubMed ID: 10864683
[TBL] [Abstract][Full Text] [Related]
17. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
Mansky LM; Pearl DK; Gajary LC
J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
[TBL] [Abstract][Full Text] [Related]
18. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
Bisset LR; Lutz H; Böni J; Hofmann-Lehmann R; Lüthy R; Schüpbach J
Antiviral Res; 2002 Jan; 53(1):35-45. PubMed ID: 11684314
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus.
Chen H; McBroom DG; Zhu YQ; Gold L; North TW
Biochemistry; 1996 May; 35(21):6923-30. PubMed ID: 8639644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
